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Abstract
Background: The employment of well characterized test samples prepared from authenticated, high quality
medicinal plant materials is key to reproducible herbal research. The present study aims to demonstrate a quality
assurance program covering the acquisition, botanical validation, chemical standardization and good
manufacturing practices (GMP) production of IBS-20, a 20-herb Chinese herbal formula under study as a potential
agent for the treatment of irritable bowel syndrome.
Methods: Purity and contaminant tests for the presence of toxic metals, pesticide residues, mycotoxins and
microorganisms were performed. Qualitative chemical fingerprint analysis and quantitation of marker compounds
of the herbs, as well as that of the IBS-20 formula was carried out with high-performance liquid chromatography
(HPLC). Extraction and manufacture of the 20-herb formula were carried out under GMP. Chemical standardization
was performed with liquid chromatography-mass spectrometry (LC-MS) analysis. Stability of the formula was
monitored with HPLC in real time.
Results: Quality component herbs, purchased from a GMP supplier were botanically and chemically authenticated
and quantitative HPLC profiles (fingerprints) of each component herb and of the composite formula were
established. An aqueous extract of the mixture of the 20 herbs was prepared and formulated into IBS-20, which
was chemically standardized by LC-MS, with 20 chemical compounds serving as reference markers. The stability of
the formula was monitored and shown to be stable at room temperature.
Conclusion: A quality assurance program has been developed for the preparation of a standardized 20-herb
formulation for use in the clinical studies for the treatment of irritable bowel syndrome (IBS). The procedures
developed in the present study will serve as a protocol for other poly-herbal Chinese medicine studies.
Background
Herbal medicines, whether in the form of single herb
phytomedicine or multiple herb mixtures, are popular
around the world. However, evidence of efficacy and
safety has not been well documented [1]. Lack of effec-
tive quality assurance affects the efficacy and safety
assessment of herbal products [1-7]. For valid pharma-
cological or clinical efficacy evaluations, a standardized
single batch clinical formulation should be employed. As
part of a research project to evaluate the therapeutic
potential of a 20-herb Chinese medicine formula (the
IBS-20 formula) for treating irritable bowel syndrome
(IBS), we have developed and tested a quality assurance
program for the production of the multi-herb prepara-
tion. IBS affects 10-20% of the global population [8] and
it has not been successfully treated with conventional
medications such as bulking, smooth muscle relaxant,
prokinetic and psychotropic agents, nor loperamide and
peppermint oil [9].
We are presently conducting a clinical study of a 20-
herb Chinese medicine formula (IBS-20) to determine
its efficacy potential in the treatment of this disorder.
To insure the validity and reproducible results in con-
ducting this study, we established a robust quality
assurance (QA)/quality control (QC) program. The
present paper describes the methods employed, cover-
ing all aspects of the production of IBS-20 from source
material acquisition, botanical validation, chemical
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tocols established in this study may be used as a
model for the quality assurance of other herbal
products.
Methods
Plant materials
The component herbs in the formula are as follows:
Pogostemon cablin (herb) (4.5%, w/w), Angelica dahurica
(root) (2%), Artemisia scoparia (herb) (13%), Atracty-
lodes macrocephala (rhizome)(9%), Aucklandia lappa
(root) (3%), Bupleurum chinense (root) (4.5%), Citrus
reticulate (fruit peel) (3%), Codonopsis pilosula (root)
(7%), Coix lacryma-jobi (seed) (7%), Coptis chinensis
(rhizome) (3%), Fraxinus rhynchophylla (bark) (4.5%),
Glycyrrhiza uralensis (root) (4.5%), Magnolia officinalis
(bark) (4.5%), Paeonia lactiflora (root)(3%), Plantago
asiatica (seed) (4.5%), Phellodendron amurense (bark)
(4.5%), Poria cocos (fruiting body) (4.5%), Saposhnikovia
divaricata (root) (3%), Schisandra chinensis (fruit) (7%)
and Zingiber officinale (rhizome) (4.5%). All 20 herbs
were acquired in the prescribed proportions (% w/w)
from Zhixin Chinese Pharmaceutical Co. Ltd. (Guangz-
hou, China). The aggregate weight of the 20 herbs was
400 kg (Additional File 1). Voucher samples (#IBS-01 to
IBS-20) were deposited at the herbarium of the School
of Chinese Medicine, Chinese University of Hong Kong
(Hong Kong SAR, China). The individual bulk herb
samples were stored in air-tight containers kept in air-
conditioned environment until use. The herbs were
identified in both Chinese and botanical (Latin bino-
mial) names. When two or more species share the same
Chinese name, only one species was selected for chemi-
cal and biological/clinical studies.
Botanical authentication
All 20 herbs were authenticated macroscopically and
microscopically. Macroscopic examinations included
measurements of appearance, size, shape, color, tex-
ture, odor, taste, fracture and other characteristics of a
herb according to pharmacopoeias [10-13]. Micro-
scopic examinations determined characteristic elements
of each herb in both tissue and powder forms. In cross
sectional examination, herbal material was softened by
immersion in water, alcohol or glycerin prior to sec-
tioning. Sliced tissue, prepared with a microtome, was
mounted on a glass microscope slide and clarified with
chloral hydrate, lactochloral and/or sodium hypochlor-
ite, followed by phloroglucinol, potassium iodide or
Sudan Red. In powder analysis, each herbal material
was pulverized to 65-mesh in size, mounted on a
microscope slide, cleared with chloral hydrate, lacto-
chloral and/or sodium hypochlorite, and then exam-
ined for the presence, size, shape and numbers of
characteristic elements and inclusions such as vessels,
calcium crystals, crystalline fibers, stone cells and
starch grains. The examination protocols followed the
World Health Organization (WHO) Quality Control
Methods for Medicinal Plant Materials [14], the Phar-
macopoeia of the People’s Republic of China (CP) [10]
and the Hong Kong Chinese Materia Medica Standards
(HKCMMS) [11-13]. The recorded macroscopic and
microscopic data for each herb were verified against
those in the CP and/or the HKCMMS, coupled with
visual comparison with available reference samples.
Reference marker compounds and reagents
Reference marker compounds for qualitative and quan-
titative high performance liquid chromatography
(HPLC) were obtained from the National Institute for
the Control of Pharmaceutical and Biological Products
(Beijing, China) and further validated by mass spectro-
metry (MS) and nuclear magnetic resonance spectro-
scopy (NMR) and purity (>98%) analysis with HPLC
and/or liquid chromatography-mass spectrometry (LC-
MS). Chemicals and general solvents were of reagent
grade and HPLC solvents were of HPLC grade (BDH,
United Kingdom).
Purity and contaminant determination
Purity rubric tests, including foreign matters, total ash,
acid-insoluble ash, water and extractive contents, were
carried out according to the CP or HKCMMS [10-13].
Determination of heavy metals (arsenic, cadmium, mer-
cury, and lead), pesticides, microbials and microbial
toxin (aflatoxin) was carried out according to the
HKCMMS [11-13]. Briefly, for heavy metal analysis, the
herbal matrix was dissolved by microwave-assisted acid
digestion, and the presence and quantity of mercury,
l e a d ,a r s e n i c ,a n d / o rc a d m i u m ,i fa n y ,w e r ed e t e r m i n e d
by inductively coupled plasma-mass spectrometry (ICP-
MS). Pesticide residues (e.g., aldrin, dieldrin, chlordane,
dichlorodiphenyltrichloroethane, endrin, heptachlor,
hexachlorobenzene, hexachlorocyclohexane isomers, lin-
dane and quintozene) were quantitatively determined
with gas chromatography (GS). Mycotoxins (aflatoxins
B1,B 2,G 1 and G2) were detected as previously described
[11-13,15]. Microorganism examinations included total
bacteria, mould and yeast, Escherichia coli and Salmo-
nella counts as described in the CP [10].
Chemical standardization
Chromatographic fingerprint analysis HPLC finger-
printing with one or more reference markers was
carried out according to the HKCMMS and/or CP
[10-13]. As an example, the procedure used for Rhi-
zoma Coptidis (Huanglian) is described here. The herb
was ground to powder, extracted in MeOH by
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matographic system consisted of an Agilent 1100
HPLC system (Agilent Technologies, USA) equipped
with a secondary pump, a diode-array detector, an
autosampler, and a column compartment, an Alltech
Alltima C18 column (4.6 × 250 mm) (Alltech, USA)
packed with 5 μm diameter particles and an Alltech
Alltima guard column (7.5 × 4.6 mm, 5 μm) (Alltech,
USA); solvent system: 0.1% trifluoroacetic acid (%, v/v)
(A) and acetonitrile (%, v/v) (B) with a linear gradient
elution, 0% B-50% B at 0-48 minutes, 50% B-100% B at
48-55 minutes, 100% B was held for five minutes; flow
rate: 1.0 ml/min; detection: 346 nm; reference marker:
berberine. Information of the reference marker com-
pounds for each herb is available in Additional File 1.
Quantitative analysis
Quantitative determination of selected marker compound
(s) in each herb was performed with HPLC analysis. As
an example, the quantitative analysis of Cortex Magnoliae
Officinalis (Houpo) is described here. Preparation of the
herb and the HPLC setup were the same as described
above. The mobile phase contained 0.4% formic acid and
acetonitrile (35:65); flow rate: 1 ml/min; detection: 294
nm. Information of the reference marker compounds for
each herb is available in Additional File 1.
Inter-laboratory methods validation
Inter-laboratory validation of fingerprint and quantita-
tive HPLC analytical protocols were carried out in
laboratories at the Chinese University of Hong Kong
and the University of Western Sydney prior to use. Both
laboratories followed the identical experimental proto-
cols and the results were critically compared.
Production of herbal extracts and the IBS-20 formula
T h e2 0d r i e dh e r b sw e r ei n d i v i d u a l l yr e d u c e di ns i z eb y
milling or slicing and mixed in the prescribed propor-
tion (% w/w), followed by extraction with water under
GMP at the Hong Kong Institute of Biotechnology
(Hong Kong Special Administrative Region, China).
Briefly, the herb mixture (400 kg) was decocted with 10-
fold (w/v) of boiling distilled water for 60 minutes,
cooled and collected. After fresh boiling water was
added, the mixture was decocted for a second time. The
cooled extracts were pooled, filtered, concentrated and
spray dried to obtain a powder (34% yield w/w based on
raw herbs). An aliquot was set aside for chemical and
pre-clinical biological studies. The remaining powdered
extract was then formulated with water-soluble starch
(excipient) in a ratio of 1:1 into the clinical product in
the form of an aluminum foil packed sachet.
Chemical standardization of the IBS-20 formula
Chemical standardization of the clinical herbal extract
with selected reference markers was performed with
HPLC coupled with diode array detection and atmo-
spheric pressure chemical ionization mass spectrometry
(HPLC-DAD-APCIMS) analysis. Briefly, the powdered
extract was sonicated in MeOH for 30 minutes and fil-
tered through a cellulose syringe filter. An aliquot (10
μl) of filtrate was injected into an Agilent 1100 HPLC
system equipped with an Alltech Alltima C18 column
(4.6 × 250 mm, 5 μm diameter). The mobile phase con-
sisted of 0.1% trifluoroacetic acid in water (v/v) (A) and
acetonitrile (B) with the gradient elution conditions as
follows: 12% B-13% B at 0-10 minutes, 13% B - 16% B
at 10-40 minutes, 16% B-36.4% B at 40-67 minutes,
36.4% B-60% B at 67-100 minutes, from 100-120 min-
utes a gradient was applied to 100% B and was held for
five minutes, followed by a 10-minute equilibration per-
iod at 12% B; flow rate: 1.5 ml/min; temperature: 27.5°C
(constant). For detection, an Agilent 1100 series LC/
MSD trap (Agilent Technologies, USA) was connected
to the HPLC system via an APCIMS interface. Ultra-
high purity helium was used as the collision gas and
high purity nitrogen as the nebulizing gas. The opti-
mized parameters in the positive ionization mode were
as follows: nebulizer gas pressure: 50 psi; dry gas flow:
5.0 l/min; dry temperature: 350°C; vaporizer tempera-
ture: 400°C; full-scan MS analysis in the range of m/z
100-2200. The reference marker compounds present in
t h es a m p l ew e r ei d e n t i f i e db yr e t e n t i o nt i m e ,M Sf r a g -
mentation and UV spectra.
Stability monitoring
The stability of the chemically standardized herbal for-
mula was monitored in real time over a period of at
least one year. The HPLC fingerprint profiles as well as
the quantitative content of eight selected major marker
compounds in the clinical formula were measured on
days 0, 2, 3, 7, 14, 30, 60, 90, 180, 360, 450 post-produc-
tion with HPLC and LC-MS respectively.
Results and discussion
During the selection of herbs, we paid special attention to
the cases where the Chinese names correspond to more
than one species. For example, Cortex Phellodendri refers
to the bark of either Phellodendron amurense or Phello-
dendron chinense which are similar in macroscopic
appearance and used interchangeably in Chinese medicine.
Our studies in support of the HKCMMS [11] revealed sig-
nificant differences in microscopic and chemical profiles
of the two species using thin-layer chromatographic (TLC)
and HPLC fingerprints as well as differences in contents
using quantitative HPLC analysis. Microscopically, the
cortex of Phellodendron chinense is broader than that of
Phellodendron amurense ( F i g u r e1 ) ,w h i l et h es t o n ec e l l s
are more abundant and scattered in the outer layer of
phloem of the former species (Figure 1a) but are sparsely
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cally, the marker compound profiles also differ signifi-
cantly (Figure 2). In Phellodendron chinense (Figure 2a),
berberine predominates while palmatine is not discernible.
On the other hand, both berberine and palmatine are pre-
sent and appear to be similar in concentration in the cor-
tex of Phellodendron amurense (Figure 2b). Thus, to
ensure chemically and biologically reproducible batches,
we decided to use the cortex of Phellodendron amurense
in our preparation.
Purity rubric tests indicated that the herbs met the
limits established by the CP and/or HKCMMS [10-13]
(in the cases where regulatory standards are available)
(Table 1). Tests for contaminants showed that none of
the 20 herbs exceeded the standards established by the
CP and/or HKCMMS [10-13] (Table 2).
Each herb possesses a unique chemical profile of sec-
ondary metabolites which may be used as marker com-
pounds for identification and standardization purposes.
Some of these marker compounds have been related to
the therapeutic efficacy of the herbs, as exemplified by
our recent discovery of magnolol and honokiol as the
active antispasmodic effects of Cortex Magnolia Offici-
nalis [16]. Therefore, the marker content, especially that
of biologically active compounds, may be used to con-
firm both the identity and quality of a herb. Additional
File 1 summarizes the status of the qualitative (finger-
printing) and quantitative (HPLC) analyses of the herbs.
Figure 3 shows the HPLC fingerprint of Rhizoma Copti-
dis as an example, whereas Table 3 provides the quanti-
tative results of individual herbs. For those herbs that
have CP and/or HKCMMS limits for the markers, the
Figure 1 Microscopic features of cross section.( a )Phellodendron chinensis bark. (b). Phellodendron amurense bark 1: Cork; 2: Cortex; 3: Stone
cells; 4: Prisms of calcium oxalate; 5: Phloem; 6: Phloem fibres and crystal fibres; 7: Phloem rays.
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cases.
Inter-laboratory validation of fingerprint and quantita-
tive HPLC demonstrated that the absolute deviation from
mean (ADM) values of honokiol and magnolol in Cortex
Magnoliae Officinalis were 0.43 and 1.11% respectively,
confirming method reproducibility of the present study
(Table 4). Similar results were obtained for all other herbs
and no significant discrepancies were noted among the
findings in Hong Kong and Australian laboratories.
The chemical standardization of the IBS-20 formula
employed a HPLC-DAD-APCIMS system (Figure 4).
Mass spectral analysis revealed 20 marker compounds
attributable to ten herbs, of which eight markers were
sufficient for quantitative estimation (Table 5). The fact
that not all markers of the 20 herbs were detected was
most likely due to low solubility of the lipophilic mar-
kers in the aqueous decoction. For the three herbs that
have no established markers, namely, Rhizoma Atracty-
lodis Macrocephalae, Semen Plantaginis,a n dPoria,n o
attempt was made to identify any ingredient from them.
The stability results showed that the concentrations of
these compounds did not change significantly from the
date of production (day 0) to the last day of analysis,
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Figure 2 HPLC chromatograms. (a). Phellodendron chinensis bark. (b) Phellodendron amurense bark 1: palmatine; 2: berberine.
Ip et al. Chinese Medicine 2010, 5:8
http://www.cmjournal.org/content/5/1/8
Page 5 of 10Table 1 Regulatory standards and experimental results of purity and contaminant tests
Ash Extractives
Pharmaceutical name Foreign
matters
Total ash Acid-insoluble
Ash
Water
content
Water-
soluble
extractives
Ethanol-
soluble
extractives
Radix Angelicae Dahuricae – (<1.0%) 6.0%
a (4.1%) 1.5%
a (<1.0%) 14%
a (10%) – (27%) 15%
a (17%)
Herba Artemisiae Scopariae – (<1.0%) 4.0%
a (2.9%) 2.0%
a (<1.0%) 15%
a (9.7%) – (25%) – (17%)
Rhizoma Atractylodis Macrocephalae – (<1.0%) 5.0%
a (3.7%) 1.0%
a <1.0%) – (10%) – (67%) – (12%)
Radix Aucklandiae 2.0%
b (<1.0%) 4.5%
b (3.2%) 1.0%
b (<1.0%) 14%
b (10%) 65%
b (68%) 15%
b (27%)
Radix Bupleuri 2.0%
b (<1.0%) 7.7%
b (1.0%) 3.5%
b (2.8%) 5.0%
b (4.4%) 12%
b (22%) 11%
b (17%)
Pericarpium Citri Reticulatae – (<1.0%) – (4.7%) – (1.4%) 13%
a (11%) – (39%) – (39%)
Radix Codonopsis 1.0%
b (<1.0%) 6.0%
b (4.1%) 2.5%
b (<1.0%) 12%
b (10%) 41%
b (60%) 21%
b (52%)
Semen Coicis 2.0%
a (<1.0%) 3.0%
a (2.3%) – (<1.0%) 15%
a (9.9%) – (6.0%) 5.5%
a (6.0%)
Rhizoma Coptidis 2.0%
b (<1.0%) 5.0%
b (2.5%) 2.5%
b (<1.0%) 12%
b (7.5%) 17%
b (23%) 14%
b (19%)
Cortex Fraxini – (<1.0%) 8.0%
a (4.7%) – (1.5%) 7.0%
a (6.5%) – (8.0%) 8.0%
a (8.7%)
Radix et Rhizoma Glycyrrhizae Praeparata cum Melle – (<1.0%) 5.0%
a (3.1%) 1.0%
a (<1.0%) 10%
a (8.1%) – (47%) – (43%)
Cortex Magnoliae Officinalis 1.0%
b (<1.0%) 8.0%
b (4.50%) 3.5%
b (1.6%) 12%
b (8.3%) 3.0%
b (8.0%) 5.0%
b (9.0%)
Radix Paeoniae Alba 1.0%
b (<1.0%) 4.0%
b (2.1%) 1.0%
b (<1.0%) 14%
b (7.1%) 21%
b (22%) 16%
b (17%)
Semen Plantaginis – (<1.0%) 6.0%
a (3.2%) 2.0%
a (<1.0%) 12%
a (10%) – (12%) – (3.3%)
Cortex Phellodendri Amurensis 1.0%
b (<1.0%) 8.5%
b (7.3%) 1.0%
b (<1.0%) 11%
b (8.7%) 9.0%
b (17%) 12%
b (16%)
Herba Pogostemonis 2.0%
a (<1.0%) 11%
a (8.6%) 4.0%
a (2.3%) 14%
a (9.1%) – (14%) 2.5%
a (10%)
Poria – (<1.0%) 4.0%
a (2.4%) 2.0%
a (<1.0%) 15%
a (9.5%) – (2.0%) – (2.6%)
Radix Saposhnikoviae 2.0%
b (<1.0%) 7.0%
b (5.1%) 2.5%
b (1.8%) 13%
b (7.7%) 22%
b (27%) 19%
b (25%)
Fructus Schisandrae Chinensis 1.0%
a (<1.0%) – (4.5%) – (1.4%) – (12%) – (30%) – (31%)
Rhizoma Zingiberis Praeparatum – (<1.0%) 7.0%
a (4.6%) – (<1.0%) – (5.8%) – (13%) – (7.8%)
Note: Data in parentheses are experimental results of the samples.
a Limit required by the Pharmacopoeia of the People’s Republic of China (2005 edition).
b Limit required by the Hong Kong Chinese Materia Medica Standards.
Table 2 Limits and experimental results of toxic contaminant tests
Test Limit (maximum) Herbal formula
Heavy metals:
Arsenic (As) 2.0 mg/kg
b 0.30 mg/kg
Cadmium (Cd) 0.3 mg/kg
b 0.13 mg/kg
Mercury (Hg) 0.2 mg/kg
b Not detectable
Lead (Pb) 5.0 mg/kg
b 0.34 mg/kg
Pesticide residues:
Aldrin and dieldrin (sum of) 0.05 mg/kg
b Not detectable
Chlordane (sum of cis-, trans- and oxychlordane) 0.05 mg/kg
b Not detectable
DDT (sum of p,p’-DDT, o,p’-DDT, p,p’-DDE and p,p’-TDE) 1.0 mg/kg
b Not detectable
Endrin 0.05 mg/kg
b Not detectable
Heptachlor (sum of heptachlor and heptachlor epoxide) 0.05 mg/kg
b Not detectable
Hexachlorobenzene 0.1 mg/kg
b Not detectable
Hexachlorocyclohexane isomers (a-, b- and δ- hexachlorocyclohexane) 0.3 mg/kg
b Not detectable
Lindane (g-hexachlorocyclohexane) 0.6 mg/kg
b Not detectable
Quintozene (sum of quintozene, pentachloroaniline and methyl pentachlorophenyl sulphide) 1.0 mg/kg
b Not detectable
Mycotoxins:
Aflatoxin B1 5 μg/kg
b Not detectable
Sum of aflatoxins B1, B2, G1 and G2 10 μg/kg
b Not detectable
Microbiological:
Total plate counts 1000 colony/g
a < 10 colony/g
Yeast and mould 100 colony/g
a < 10 colony/g
Escherichia coli Absent
a Absent
Salmonella species Absent Absent
a Limit required by the Pharmacopoeia of the People’s Republic of China (2005 edition).
b Limit required by the Hong Kong Chinese Materia Medica Standards.
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Figure 3 Chromatographic fingerprint of Rhizoma Coptidis extract. Number shows in the bracket(s) represent the relative retention of the
peak to the marker peak: 1 (0.81); 2 (0.88); 3 (0.89, jatrorrhizine); 4 (0.90); 5 (0.93, coptisine); 6 (0.98, palmatine); 7 (marker, berberine).
Table 3 Quantitative assay results of the component herbs
Pharmaceutical name Reference marker Limit
(minimum)
Analytical results
Radix Angelicae Dahuricae Imperatorin 0.080%
a 0.081%
Herba Artemisiae Scopariae Chlorogenic acid – 0.31%
Rhizoma Atractylodis Macrocephalae –– –
Radix Aucklandiae Sum of costunolide and dehydrocostus lactone 2.2%
b 2.7%
Radix Bupleuri Saikosaponin a 0.16%
b 0.43%
Pericarpium Citri Reticulatae Hesperidin 3.5%
a 6.5%
Radix Codonopsis Lobetyolin 0.029%
b 0.069%
Semen Coicis Glycerol trioleate 0.50
a 1.1%
Rhizoma Coptidis Berberine
Palmatine
4.1%
b
0.30%
b
7.4%
1.8%
Cortex Fraxini Sum of aesculetin and esculin 1.0%
a 2.1%
Radix et Rhizoma Glycyrrhizae Praeparata cum Melle Glycyrrhizic acid – 2.7%
Cortex Magnoliae Officinalis Sum of magnolol and honokiol 2.0%
b 2.3%
Radix Paeoniae Alba Paeoniflorin 1.6%
a 1.8%
Semen Plantaginis –– –
Cortex Phellodendri Amurensis Berberine
Palmatine
0.33%
b
0.18%
b
0.95%
0.40
Herba Pogostemonis Patchouli alcohol 0.10%
a 0.23%
Poria –– –
Radix Saposhnikoviae Sum of prim-O-Glucosylcimifugin and 5-O-methylvisammioside 0.24%
b 0.42%
Fructus Schisandrae Chinensis Schisandrin 0.40%
a 0.66%
Rhizoma Zingiberis Praeparatum 6-Gingerol – 0.31%
a Limit required by the Pharmacopoeia of the People’s Republic of China (2005 edition).
b Limit required by the Hong Kong Chinese Materia Medica Standards.
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under the storage conditions (Figure 5).
Conclusion
A QA/QC program involving good supply practice acqui-
sition, botanical validation, chemical profiling of the
component herbs, as well as the establishment of a che-
mical standardization protocol and stability monitoring
has been implemented on a 20-herb botanical prepara-
tion, the IBS-20 formula. The results of this study
Table 4 Inter-laboratory validation of quantitative assay
of Cortex Magnoliae Officinalis
Percentage content (%) ADM (%)
CUHK result UWS result
Honokiol 0.8355 0.8427 0.43
Magnolol 1.4815 1.5148 1.11
Note: ADM (absolute deviation from mean) = (| D1 - mean|/mean) × 100%,
where mean = (D1+D2)/2; D1 = the first value, D2 = the second value.
CUHK: Chinese University of Hong Kong.
UWS: University of Western Sydney.
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Figure 4 Chromatographic fingerprint of the IBS-20 formula.
Table 5 Identification of markers in the HPLC fingerprint of the formula by LC-MS analysis
APCI MS Data (Positive Ion)
Peak Identification Time (min) M/QMIP
a Other Peaks MS
2 of M/QMIP Plant Source
b Content in formulation
(mg/kg)
1 Esculin 6.4 341 (M+H)
+ 179 179 FR
2 Chlorogenic acid 10.3 355 (M+H)
+ 163 163 AS
3 Aesculetin 12.0 179 (M+H)
+ 134, 123, 109 FR 310
4 Paeoniflorin 18.8 498 (M+H2O)
+ 301, 179 301, 179 PL
5 prim-O-Glucosylcimifugin 23.8 469 (M+H)
+ 307 SD
6 Magnoflorine 32.2 342 (M)
+ 297, 265 CC, PA
7 Liquiritin 35.9 419 (M+H)
+ 307, 257 GU
85 - O-Methylvisamminoside 49.9 453 (M+H)
+ 291 290 SD
9 Hesperidin 52.0 610 (M)
+ 465, 449, 303 463 CR 1460
10 Columbamine 60.2 338 (M)
+ 323, 294 CC
11 Jatrorrhizine 61.3 338 (M)
+ 323, 294 CC
12 Epiberberine 61.3 336 (M)
+ CC
13 Coptisine 61.4 320 (M)
+ 304, 292 CC
14 Palmatine 66.5 352 (M)
+ 337, 308 CC, PA 420
15 Berberine 67.3 336 (M)
+ 321, 292 CC, PA 1620
16 Glycyrrhizic acid 76.2 823 (M+H)
+ 647, 471, 453, 406 GU 780
17 Schisandrin 81.8 433 (M+H)
+ 415 SC 140
18 Honokiol 93.3 266 (M)
+ 263 MO 63
19 Magnolol 98.6 266 (M)
+ 261 MO 93
20 Schisandrin A 107.7 417 (M+H)
+ 402, 347, 316 SC
Note: Peak number refers to the chromatographic fingerprint of the clinical preparation (Figure 4). Peaks 6, 10, 12, and13 were identified by LC-MS/MS2 analysis
based on the literature values [17,18] and other peaks were identified by comparison of authentic chemicals. Jatrorrhizine and epiberberine (peaks 11, 12) were
co-eluted with the same retention times.
a Molecular or quasi-molecular ion peak;
b FR: Fraxinus rhynchophylla;A S :Artemisia scoparia;P L :Paeonia lactiflora;S D :Saposhinikovia divaricata;G U :Glycyrrhiza
uralensis; CR: Citrus reticulata;C C :Coptis chinensis; PA: Phellodendron amurense;S C :Schisandra chinensis; MO: Magnolia officinalis.
Ip et al. Chinese Medicine 2010, 5:8
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Page 8 of 10demonstrate that it is possible to establish a QA/QC pro-
gram to monitor the quality of poly-herbal formulations
employing botanical and chemical methods. In particular,
the generation of a fingerprint HPLC chromatographic
protocol in which the identities of a series of appropriate
marker compounds, including relevant biologically active
constituents, were identified for use in product standardi-
zation, coupled with a stability study procedure involving
the LC-MS quantitation of major chemical markers,
represent major advances in the development of quality
control methods for poly-herbal Chinese medicine pro-
ducts for clinical studies and therapy.
Figure 5 Stability of the IBS-20 formula. The ratio was calculated by the content of the marker at the date of measurement to that at the
starting date.
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Page 9 of 10Additional file 1: Summary of the herbs and their chemical marker.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1749-8546-5-8-
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